Abel Hall LLC Has $628,000 Stake in Pfizer Inc. $PFE

Key Points

• Abel Hall LLC increased its stake in Pfizer Inc. by 125.1% during the second quarter, owning a total of 25,900 shares valued at $628,000 according to the latest SEC filing.
• Multiple institutional investors have recently acquired positions in Pfizer, contributing to 68.36% of the stock being owned by such entities.
• Pfizer's stock currently has a consensus rating of "Hold" with a target price of $28.41, after recent ratings adjustments from various research analysts.

Abel Hall LLC raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 125.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,900 shares of the biopharmaceutical company's stock after acquiring an additional 14,395 shares during the period. Abel Hall LLC's holdings in Pfizer were worth $628,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the first quarter worth about $27,000. North Capital Inc. acquired a new position in shares of Pfizer during the first quarter worth about $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter worth about $28,000. Horizon Financial Services LLC acquired a new position in shares of Pfizer during the first quarter worth about $35,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer during the first quarter worth about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on PFE shares. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a report on Saturday, September 27th. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. UBS Group reiterated a "neutral" rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Morgan Stanley upped their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $28.41.

Pfizer Stock Performance

PFE opened at $26.27 on Wednesday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The stock has a market cap of $149.36 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 0.86 and a beta of 0.55. The business has a 50 day moving average of $24.76 and a 200-day moving average of $24.14. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period last year, the firm posted $0.60 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.